Beyond targeted

Tango Therapeutics is a biotechnology company developing novel medicines for patients by discovering and drugging context-dependent vulnerabilities in cancers. Tango was launched in 2017 by Third Rock Ventures, and is headquartered in Cambridge, Mass. For more information, please visit

Year Invested: 2017
Location: Cambridge, Mass.

Recent News

September 26, 2017
Tango Therapeutics Named a “Fierce 15” Company by FierceBiotech

September 25, 2017
Tango Therapeutics Appoints Barbara Weber, MD, as Chief Executive Officer

March 30, 2017
Third Rock Ventures Launches Tango Therapeutics with $55 Million Series A Investment

Read More News

Associated Team Members

Barbara Weber, M.D.
Venture Partner

Cary Pfeffer, M.D.

Alexis Borisy